What is Nykode Therapeutics AS's (NYKD.OL) StockRank?

MoatMap's StockRank for Nykode Therapeutics AS (NYKD.OL) is 46/100, with a Hold signal. This is a composite score combining Quality (35), Value (34), and Momentum (67) factor ranks across MoatMap's 20,000+ stock universe.

Does Nykode Therapeutics AS have an economic moat?

Nykode Therapeutics AS (NYKD.OL) has a Quality factor score of 35/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Nykode Therapeutics AS a buy, hold, or sell?

MoatMap's current signal for Nykode Therapeutics AS (NYKD.OL) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Nykode Therapeutics AS in?

Nykode Therapeutics AS (NYKD.OL) operates in the Healthcare sector, specifically the Biotechnology industry (Norway).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

NYKD.OL

HOLDREMOVE

Nykode Therapeutics AS · Healthcare · Norway · $109M · Avg Vol: $254K/d

StockRank

P/E (TTM)

—

ROE

-13.5%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Nykode Therapeutics is a clinical-stage biotech company. It is pre-revenue, highly speculative, and lacks the established cash flows, high ROIC, and structural moats required by our Terry Smith and Warren Buffett lenses.

COMPANY DESCRIPTION

Nykode Therapeutics AS is a clinical-stage biopharmaceutical company specializing in targeted immunotherapy, specifically through its proprietary Vaccibody platform which targets antigen-presenting cells. The company develops tailored vaccines for oncology and infectious diseases, supported by high-profile partnerships with Roche, Genentech, and Regeneron. Its competitive moat is built on its unique modular vaccine technology and robust intellectual property portfolio.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0.7M	1.3M	0.9M	0	10.0%
EPS	-0.02	-0.01	-0.01	-0.00	—
Shares	294.7M	326.5M	326.5M	326.5M	+10.8%
Debt	0.6M	0.6M	0.4M	0.3M	-22.7%
Equity	16.2M	17.7M	14.1M	9.4M	-16.5%
Op CF	-2.1M	-10.0M	-5.3M	-3.0M	—
Inv CF	1.1M	0.7M	0.7M	0.4M	—
Fin CF	37,156	4.6M	-0.1M	-3.5M	—

PRICE (1Y)+1.2%

SMA 50SMA 200

$0.33

RSI (14)

41.2

52W High

$0.42

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-18.7%29.0

ROE

-13.5%33.2

GP/Assets

5.1%18.9

Op. Margin

-2723.3%4.5

FCF/Assets

-169.5%0.6

Piotroski

321.6

Int. Cover

-50.0x6.0

D/E Ratio

0.03x80.3

Current Ratio

12.66x90.5

Value

P/E (TTM)

—N/A

EV/EBITDA

-3.9x25.0

P/FCF

—N/A

P/B

0.1x99.3

P/S

203.3x5.2

Div Yield

—N/A

Momentum

52W High %

79%68.5

RS 6M

7%75.1

SMA 50/200

1.20x89.2

EPS Rev 4W

+80.5%99.4

EPS Rev 12W

—N/A

EPS Improve

—63.7

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$109M

P/E (Forward)

-23.1x

Gross Margin

100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NYKD.OL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
NYKD.OL	Nykode Therapeutics AS(you)	$109M	46	HOLD
AZT.OL	ArcticZymes Technologies ASA	$107M	45	HOLD
TRMED.OL	Thor Medical ASA	$157M	20	SELL
CRNA.OL	Circio Holding ASA	$232M	20	SELL
ZLNA.OL	Zelluna ASA	$51M	20	SELL
PHO.OL	Photocure ASA	$166M	70	BUY
VISTN.OL	Vistin Pharma ASA	$93M	99	STRONG BUY
MEDI.OL	Medistim ASA	$438M	86	STRONG BUY

Peer medians: ROE 16.1% · P/E 23.0x · Gross margin 93.6%

Nykode Therapeutics AS (NYKD.OL) — Stock Score Summary

Nykode Therapeutics AS (NYKD.OL) has a MoatMap StockRank of 46/100 based on Quality (35/100), Value (34/100), and Momentum (67/100) factor scores. The current signal is HOLD. Nykode Therapeutics is a clinical-stage biotech company. It is pre-revenue, highly speculative, and lacks the established cash flows, high ROIC, and structural moats required by our Terry Smith and Warren Buffett lenses.

Key Financial Metrics

Price	$0.33
Market Cap	$109M
P/E (Forward)	-23.10
Price/Book	0.14
Return on Equity	-13.5%
Return on Invested Capital	-18.7%
Debt/Equity	2.67
Gross Margin	100.0%
Operating Margin	-2723.3%
Revenue Growth	75.2%
Free Cash Flow	$-2M

Nykode Therapeutics AS operates in the Biotechnology industry, part of the Healthcare sector (Norway).

Frequently Asked Questions

What is Nykode Therapeutics AS’s (NYKD.OL) StockRank?: MoatMap’s StockRank for Nykode Therapeutics AS (NYKD.OL) is 46/100, with a Hold signal. It is a composite of Quality (35), Value (34), and Momentum (67) factor ranks across MoatMap’s 20,000+ stock universe.
Does Nykode Therapeutics AS have an economic moat?: Nykode Therapeutics AS (NYKD.OL) has a Quality factor score of 35/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Nykode Therapeutics AS a buy, hold, or sell?: MoatMap’s current signal for Nykode Therapeutics AS (NYKD.OL) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Nykode Therapeutics AS in?: Nykode Therapeutics AS (NYKD.OL) operates in the Healthcare sector, specifically the Biotechnology industry (Norway).